

## Publicazioni

Prof. Riccardo Valdagni

1. Verzoni E, Grassi P, Ratta R, Niger M, De Braud F, **Valdagni R**, Procopio G. Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors. *Ther Adv Med Oncol*. 2016 Sep;8(5):323-30. doi: 10.1177/1758834016656493. Epub 2016 Jul 5.
2. Improta I, Palorini F, Cozzarini C, Rancati T, Avuzzi B, Franco P, Degli Esposti C, Del Mastro E, Girelli G, Iotti C, Vavassori V, **Valdagni R**, Fiorino C. Bladder spatial-dose descriptors correlate with acute urinary toxicity after radiation therapy for prostate cancer. *Phys Med*. 2016 Aug 25. pii: S1120-1797(16)30900-0. doi: 10.1016/j.ejmp.2016.08.013. [Epub ahead of print]
3. De Santis MC, Bonfantini F, Di Salvo F, Dispinzieri M, Mantero E, Soncini F, Baili P, Sant M, Bianchi G, Maggi C, Di Cosimo S, Agresti R, Pignoli E, **Valdagni R**, Lozza L. Factors influencing acute and late toxicity in the era of adjuvant hypofractionated breast radiotherapy. *Breast*. 2016 Jul 29;29:90-95. doi: 10.1016/j.breast.2016.07.013. [Epub ahead of print]
4. Bellardita L, Damiano R, Porpiglia F, Scattoni V, Amodeo A, Bortolus R, Lapini A, Cocci A, Cicalese V, Caponera M, Mastrangelo P, Francesca F, **Valdagni R**, Taverna G, di Trapani D, Leonardi R, Minocci D, Gaboardi F, Montanari E, Conti G. Adaptation and validation of an Italian version of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI). *Eur Rev Med Pharmacol Sci*. 2016 Jul;20(13):2773-8.
5. Moore CM, Giganti F, Albertsen P, Allen C, Bangma C, Briganti A, Carroll P, Haider M, Kasivisvanathan V, Kirkham A, Klotz L, Ouzzane A, Padhani AR, Panebianco V, Pinto P, Puech P, Rannikko A, Renard-Penna R, Touijera K, Turkbey B, van Poppel H, **Valdagni R**, Walz J, Schoots I. Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force. *Eur Urol*. 2016 Jun 24. [Epub ahead of print]
6. Bokhorst LP, **Valdagni R**, Rannikko A, Kakehi Y, Pickles T, Bangma CH, Roobol MJ; PRIAS study group. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment. *Eur Urol*. 2016 Jun 18.
7. Carrara M, Giandini T, Pariani C, Pignoli E, Rancati T, **Valdagni R**, De Santis C, Lozza L. Comment on "Objective assessment in digital images of skin erythema caused by radiotherapy" [*Med. Phys.* 42, 5568-5577 (2015)]. *Med Phys*; 43(5):2687, 2016.
8. Involving a Citizens' Jury in Decisions on Individual Screening for Prostate Cancer. Mosconi P, Colombo C, Satolli R, Carzaniga S; Steering Committee; Scientific Committee. *PLoS One* ;11(1):e0143176. eCollection 2016, 2016.
9. Cozzarini C, Rancati T, Badenchini F, Palorini F, Avuzzi B, Degli Esposti C, Girelli G, Improta I, Vavassori V, **Valdagni R**, Fiorino C. Baseline status and dose to the penile bulb predict impotence 1 year after radiotherapy for prostate cancer. *Strahlenther Onkol*. 2016 Apr 14. [Epub ahead of print]
10. Landoni V, Fiorino C, Cozzarini C, Sanguineti G, **Valdagni R**, Rancati T. Predicting toxicity in radiotherapy for prostate cancer. *Phys Med*. 2016 Apr 8. pii: S1120-1797(16)00527-5. [Epub ahead of print]
11. Palorini F, Cozzarini C, Gianolini S, Botti A, Carillo V, Iotti C, Rancati T, **Valdagni R**, Fiorino C. First application of a pixel-wise analysis on bladder dose-surface maps in prostate cancer radiotherapy. *Radiother Oncol*. 2016 Mar 15. pii: S0167-8140(16)00113-4. [Epub ahead of print]
12. Bokhorst LP, Lepistö I, Kakehi Y, Bangma CH, Pickles T, **Valdagni R**, Alberts AR, Semjonow A, Strölin P, Montesino MF, Berge V, Roobol MJ, Rannikko A. Complications after prostate biopsies in men on active surveillance and its effect on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) study. *BJU Int*. 2016 Jan 14. [Epub ahead of print]
13. Di Muzio NG, Fodor A, Noris Chiorda B, Broggi S, Mangili P, **Valdagni R**, Dell'Oca I, Pasetti M, Deantoni CL, Chiara A, Berardi G, Briganti A, Calandrino R, Cozzarini C, Fiorino C. Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study. *Clin Oncol (R Coll Radiol)*. 2016 Mar 5. [Epub ahead of print]
14. Bruinsma SM, Bangma CH, Carroll PR, Leapman MS, Rannikko A, Petrides N, Weerakoon M, Bokhorst LP, Roobol MJ; Movember GAP3 consortium [**Valdagni R**]. Active surveillance for prostate cancer: a narrative review of clinical guidelines. *Nat Rev Urol*. 2016 Jan 27. [Epub ahead of print] Review.
15. Capocaccia R, Foschi R, Zucchetto A, **Valdagni R**, Nicolai N, Maffezzini M, Gatta G. Estimates of prostate cancer burden in Italy. *Cancer Epidemiol*, 40:166-72, 2016.
16. Palorini F, Rancati T, Cozzarini C, Improta I, Carillo V, Avuzzi B, Casanova Borca V, Botti A, Degli Esposti C, Pierfrancesco F, Garibaldi E, Girelli G, Iotti C, Maggio A, Palombarini M, Pierelli A, Pignoli E, Vavassori V, **Valdagni R**, Fiorino C. Multi-variable models of large International Prostate Symptoms Score worsening at the end of therapy in prostate cancer radiotherapy. *Radioth & Oncol*, 118(1):92-8, 2016.
17. Moriconi S, Scalco E, Broggi S, Avuzzi B, **Valdagni R**, Rizzo G. High quality surface reconstruction in radiotherapy: Cross-sectional contours to 3D mesh using wavelets. *Conf Proc IEEE Eng Med Biol Soc*. 2015 Aug;2015:4222-5.

18. Frigerio B, Benigni F, Luison E, Seregni E, Pascali C, Fracasso G, Morlino S, **Valdagni R**, Mezzanzanica D, Canevari S, Figini M. Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen. *Immunol Lett*. 2015 Sep 25;168(1):105-110. [Epub ahead of print]
19. Doldi V, Callari M, Giannoni E, D'Aiuto F, Maffezzini M, **Valdagni R**, Chiarugi P, Gandellini P, Zaffaroni N. Integrated gene and miRNA expression analysis of prostate cancer associated fibroblasts supports a prominent role for interleukin-6 in fibroblast activation. *Oncotarget*. 2015 Sep 8. [Epub ahead of print]
20. Cozzarini C, Rancati T, Carillo V, Civardi F, Garibaldi E, Franco P, Avuzzi B, Esposti CD, Girelli G, Iotti C, Palorini F, Vavassori V, **Valdagni R**, Fiorino C. Multi-variable models predicting specific patient-reported acute urinary symptoms after radiotherapy for prostate cancer: Results of a cohort study. *Radiother Oncol*. 2015 Aug;116(2):185-91.
21. Bokhorst LP, Alberts AR, Rannikko A, **Valdagni R**, Pickles T, Kakehi Y, Bangma CH, Roobol MJ; PRIAS study group. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers. *Eur Urol pii: S0302-2838(15)00515-1*, 2015[Epub ahead of print]
22. **Valdagni R**, Van Poppel H, Aitchison M, Albers P, Berthold D, Bossi A, Brausi M, Denis L, Drudge-Coates L, De Santis M, Feick G, Harrison C, Haustermans K, Hollywood D, Hoyer M, Hummel H, Mason M, Mirone V, Müller SC, Parker C, Saghatchian M, Sternberg CN, Tombal B, van Muilekom E, Watson M, Wesselmann S, Wiegel T, Magnani T, Costa A. Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology. *Crit Rev Oncol Hematol* 95(2):133-43, 2015.
23. Vasarainen H, Salman J, Salminen H, **Valdagni R**, Pickles T, Bangma C, Roobol MJ, Rannikko A. Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS). *World J Urol*. 2015 Mar 31. [Epub ahead of print]
24. Jerezek-Fossa BA, Colombo R, Magnani T, Fodor C, Gerardi MA, Antognoni P, Barsacchi L, Bedini N, Bracelli S, Buffoli A, Cagna E, Catalano G, Gottardo S, Italia C, Ivaldi GB, Masciullo S, Merlotti A, Sarti E, Scorsetti M, Serafini F, Toninelli M, Vitali E, **Valdagni R**, Villa E, Zerini D, De Cobelli O, Orecchia R. Urinary bladder preservation for muscle-invasive bladder cancer: a survey among radiation oncologists of Lombardy, Italy. *Tumori* 101(2):174-8, 2015
25. Bangma CH, **Valdagni R**, Carroll PR, van Poppel H, Klotz L, Hugosson J. Active Surveillance for Low-risk Prostate Cancer: Developments to Date. *Eur Urol* 67(4):646-8, 2015
26. Bellardita L, **Valdagni R**, van den Bergh R, Randsdorp H, Repetto C, Venderbos L D F, Lane J A, Korfage I J, How Does Active Surveillance for Prostate Cancer Affect Quality of Life? A Systematic Review. *Eur Urol* 67 (4):637-645
27. Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjöberg D, Assel M, Foster CS, Mitchell G, Drew K, Mæhle L, Axcrone K, Evans DG, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeneij LA, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick PJ, Bojesen A, Skytte AB, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Blanco I, Salinas M, Cook J, Rosario DJ, Buys S, Conner T, Ausems MG, Ong KR, Hoffman J, Domchek S, Powers J, Teixeira MR, Maia S, Foulkes WD, Taherian N, Ruijs M, Helderma-van den Enden AT, Izatt L, Davidson R, Adank MA, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman GJ, Zgajnar J, Tischkowitz M, Clowes VE, Susman R, Ramón y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady AF, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor DJ, Copakova L, Barwell J, Giri VN, Murthy V, Nicolai N, Teo SH, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrone U, Melia J, McKinley J, Mitra AV, Moynihan C, Rennert G, Suri M, Wilson P, Killick E; IMPACT Collaborators (**Valdagni R**), Moss S, Eeles RA. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. *Eur Urol* 66(3):489-499, 2014
28. Voigt W, Hoellthaler J, Magnani T, Corrao V, **Valdagni R**. 'Act on oncology' as a new comprehensive approach to assess prostate cancer centres - method description and results of a pilot study. *PLoS One* 9(9):e106743, 2014.
29. West C, Azria D, Chang-Claude J, Davidson S, Lambin P, Rosenstein B, De Ruyscher D, Talbot C, Thierens H, **Valdagni R**, Vega A, Yuille M. The REQUITE Project: Validating Predictive Models and Biomarkers of Radiotherapy Toxicity to Reduce Side-effects and Improve Quality of Life in Cancer Survivors. *Clin Oncol (R Coll Radiol) pii: S0936-6555(14)00341-0*, 2014
30. Gandellini P, Rancati T, **Valdagni R**, Zaffaroni N. miRNAs in tumor radiation response: bystanders or participants? *Trends Mol Med* 20(9):529:539, 2014
31. Maggio A, Magli A, Rancati T, Fiorino C, Valvo F, Fellin G, Ricardi U, Munoz F, Cosentino D, Cazzaniga LF, **Valdagni R**, Vavassori V. Daily sodium butyrate enema for the prevention of radiation proctitis in prostate cancer patients undergoing radical radiation therapy: results of a multicenter randomized placebo-controlled dose-finding phase 2 study. *Int J Radiat Oncol Biol Phys* 89(3):518-24, 2014
32. Bellardita L, Villa S, **Valdagni R**. Living with untreated prostate cancer: predictors of quality of life. *Curr Opin Urol* 24(3):311-7, 2014
33. Carillo V, Cozzarini C, Rancati T, Avuzzi B, Botti A, Borca VC, Cattari G, Civardi F, Esposti CD, Franco P, Girelli G, Maggio A, Muraglia A, Palombarini M, Pierelli A, Pignoli E, Vavassori V, Zeverino M, **Valdagni R**, Fiorino C.

Relationships between bladder dose-volume/surface histograms and acute urinary toxicity after radiotherapy for prostate cancer. *Radiother Oncol* 111(1):100-5, 2014

34. Killick E, Tymrakiewicz M, Cieza-Borrella C, Smith P, Thompson DJ, Pooley KA, Easton DF, Bancroft E, Page E, Leongamornlert D; IMPACT collaborators (**Valdagni R**), Kote-Jarai Z, Eeles RA. Telomere length shows no association with BRCA1 and BRCA2 mutation status. *PLoS One* 9(1):e86659, 2014. eCollection 2014

35. Pennati M, Lopercolo A, Profumo V, De Cesare M, Sbarra S, **Valdagni R**, Zaffaroni N, Gandellini P, Folini M. miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells. *Biochem Pharmacol* 87(4):579-97, 2014

36. Fellin G, Rancati T, Fiorino C, Vavassori V, Antognoni P, Baccolini M, Bianchi C, Cagna E, Borca VC, Girelli G, Iacopino B, Maliverni G, Mauro FA, Menegotti L, Monti AF, Romani F, Stasi M, **Valdagni R**. Long term rectal function after high-dose prostate cancer radiotherapy: Results from a prospective cohort study. *Radiother Oncol* 110(2):272-7, 2014

37. Bellardita L, Rancati T, **Valdagni R**. Editorial Comment to Health-related quality of life after carbon-ion radiotherapy for prostate cancer: A 3-year prospective study. *Int J Urol* 2013 Nov 2013

38. Horwich A1, Hugosson J, de Reijke T, Wiegel T, Fizazi K, Kataja V; Panel Members (**Valdagni R**); European Society for Medical Oncology. Prostate cancer: ESMO Consensus Conference Guidelines 2012. *Ann Oncol* 24(5):1141-62, 2013

39. Valdagni R, Rancati T. Reducing rectal injury during external beam radiotherapy for prostate cancer. *Nat Rev Urol* 10(6):345-57, 2013

40. Gandellini P, Giannoni E, Casamichele A, Taddei ML, Callari M, Piovan C, **Valdagni R**, Pierotti MA, Zaffaroni N, Chiarugi P. miR-205 Hinders the Malignant Interplay Between Prostate Cancer Cells and Associated Fibroblasts. *Antioxid Redox Signal* 20(7): 1045-59, 2014

41. Descovich M, Carrara M, Morlino S, Pinnaduwege DS, Saltiel D, Pouliot J, Nash MB, Pignoli E, **Valdagni R**, Roach M, Gottschalk AR. Improving plan quality and consistency by standardization of dose constraints in prostate cancer patients treated with CyberKnife. *J Appl Clin Med Phys* 14(5):4333, 2013

42. Procopio G, Grassi P, Testa I, Verzoni E, Torri V, Salvioni R, **Valdagni R**, de Braud F. Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. *Am J Clin Oncol*. 2013 Sep 21. [Epub ahead of print]

43. Tombal B, Alcaraz A, James N, **Valdagni R**, Irani J. Can we improve the definition of high-risk, hormone naïve, non-metastatic prostate cancer? *BJU Int* 113/2:189-99, 2014

44. Bellardita L, **Valdagni R**, Rancati T. Reply from Authors re: Laurence Klotz. Active Surveillance, Quality of Life, and Cancer-related Anxiety. *Eur Urol*. 2013; 64:37-9: Active Surveillance: Risk and Protective Factors for Quality of Life. *Eur Urol* 64(1):39-40, 2013

45. Maggio A, Carillo V, Cozzarini C, Perna L, Rancati T, **Valdagni R**, Gabriele P, Fiorino C. Impact of the radiotherapy technique on the correlation between dose-volume histograms of the bladder wall defined on MRI imaging and dose-volume/surface histograms in prostate cancer patients. *Phys Med Biol* 58(7):N115-23, 2013

46. Bellardita L, Rancati T, Alvisi MF, Villani D, Magnani T, Marengi C, Nicolai N, Procopio G, Villa S, Salvioni R, **Valdagni R**. Predictors of Health-related Quality of Life and Adjustment to Prostate Cancer During Active Surveillance. *Eur Urol* 64(1): 30-6, 2013

47. Bul M, Zhu X, **Valdagni R**, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der Schoot DK, Cornel EB, Conti GN, Boevé ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strölin P, van Muilekom E, Schröder FH, Bangma CH, Roobol MJ. Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS Study. *Eur Urol* 64(4):597-603, 2013

48. Bangma CH, Bul M, van der Kwast TH, Pickles T, Korfage IJ, Hoeks CM, Steyerberg EW, Jenster G, Kattan MW, Bellardita L, Carroll PR, Denis LJ, Parker C, Roobol MJ, Emberton M, Klotz LH, Rannikko A, Kakehi Y, Lane JA, Schröder FH, Semjonow A, Trock BJ, **Valdagni R**. Active surveillance for low-risk prostate cancer. *Crit Rev Oncol Hematol* 85(3):295-302, 2013

49. Rivoltini L, Marrari A, Castelli C, Villa S, **Valdagni R**. Don't run before you can walk. *Nat Rev Urol* 9(10):602, 2012

50. Carillo V, Cozzarini C, Chietera A, Perna L, Gianolini S, Maggio A, Botti A, Rancati T, **Valdagni R**, Fiorino C. Correlation between surrogates of bladder dosimetry and dose-volume histograms of the bladder wall defined on MRI in prostate cancer radiotherapy. *Radiother Oncol* 105(2):180-183, 2012

51. Gandellini P, Profumo V, Casamichele A, Fenderico N, Borrelli S, Petrovich G, Santilli G, Callari M, Colecchia M, Pozzi S, De Cesare M, Folini M, **Valdagni R**, Mantovani R, Zaffaroni N. miR-205 regulates basement membrane deposition in human prostate: implications for cancer development. *Cell Death Differ* 19(11):1750-60, 2012

52. **Valdagni R**, Vavassori V, Rancati T, Fellin G, Baccolini M, Bianchi C, Cagna E, Gabriele P, Mauro F, Menegotti L, Monti AF, Stasi M, Fiorino C. Increasing the risk of late rectal bleeding after high-dose radiotherapy for prostate cancer: the case of previous abdominal surgery. Results from a prospective trial. *Radiother Oncol* 103 (2):252-255, 2012

53. Magnani T, **Valdagni R**, Salvioni R, Villa S, Bellardita L, Donegani S, Nicolai N, Procopio G, Bedini N, Rancati T, Zaffaroni N. The 6-year attendance of a multidisciplinary prostate cancer clinic in Italy: incidence of management changes. *BJU Int* 110(7):998-1003, 2012
54. Carillo V, Cozzarini C, Perna L, Calandra M, Gianolini S, Rancati T, Spinelli AE, Vavassori V, Villa S, **Valdagni R**, Fiorino C. Contouring Variability of the Penile Bulb on CT Images: Quantitative Assessment Using a Generalized Concordance Index. *Int J Radiat Oncol Biol Phys* 84(3):841-846, 2012
55. Tomatis S, Rancati T, Fiorino C, Vavassori V, Fellin G, Cagna E, Mauro FA, Girelli G, Monti A, Baccolini M, Naldi G, Bianchi C, Menegotti L, Pasquino M, Stasi M, **Valdagni R**. Late rectal bleeding after 3D-CRT for prostate cancer: development of a neural-network-based predictive model. *Phys Med Biol* 57(5):1399-412, 2012
56. Bellardita, L., Graffigna, G., Donegani, S., Villani, D., Villa, S., Tresoldi, V., Marengi, C., Magnani, T., Valdagni, R. Patient's choice of observational strategy for early-stage prostate cancer, *Neuropsychological Trends*, 12 (1), 107-116, 2012
57. Bul M, Zhu X, Rannikko A, Staerman F, **Valdagni R**, Pickles T, Bangma CH, Roobol MJ. Radical Prostatectomy for Low-Risk Prostate Cancer Following Initial Active Surveillance: Results From a Prospective Observational Study. *Eur Urol.* 62(2):195-200, 2012
58. Fiorino C, Rancati T, Fellin G, Vavassori V, Cagna E, Casanova Borca V, Girelli G, Menegotti L, Monti AF, Tortoreto F, Delle Canne S, **Valdagni R**. Late Fecal Incontinence After High-Dose Radiotherapy for Prostate Cancer: Better Prediction Using Longitudinal Definitions. *Int J Radiat Oncol Biol Phys* 83(1):38-45, 2012
59. Perna L, Cozzarini C, Maggiulli E, Fellin G, Rancati T, **Valdagni R**, Vavassori V, Villa S, Fiorino C. Inter-observer variability in contouring the penile bulb on CT images for prostate cancer treatment planning. *Radiat Oncol* 24;6:123, 2011
60. **Valdagni R**. Prostate cancer units: has the time come to discuss this thorny issue and promote their establishment in Europe? *Eur Urol* 60(6):1193-1196, 2011
61. **Valdagni R**, Nahum AE, Magnani T, Italia C, Lanceni A, Montanaro P, Rancati T, Avuzzi B, Fiorino C. Long-term biochemical control of prostate cancer after standard or hyper-fractionation: Evidence for different outcomes between low-intermediate and high risk patients. *Radiother Oncol* 101(3):454-459 2011
62. Rancati T, Fiorino C, Fellin G, Vavassori V, Cagna E, Casanova Borca V, Girelli G, Menegotti L, Monti AF, Tortoreto F, Delle Canne S, **Valdagni R**. Inclusion of clinical risk factors into NTCP modelling of late rectal toxicity after high dose radiotherapy for prostate cancer. *Radiother Oncol* 100(1):124-130, 2011
63. Bul M, van den Bergh RC, Rannikko A, **Valdagni R**, Pickles T, Bangma CH, Roobol MJ. Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program. *Eur Urol* 61(2):370-377, 2012
64. **Valdagni R**, Kattan MW, Rancati T, Yu C, Vavassori V, Fellin G, Cagna E, Gabriele P, Mauro FA, Baccolini M, Bianchi C, Menegotti L, Monti AF, Stasi M, Giganti MO, Fiorino C. Is It Time to Tailor the Prediction of Radio-Induced Toxicity in Prostate Cancer Patients? Building the First Set of Nomograms for Late Rectal Syndrome. *Int J Radiat Oncol Biol Phys* 82(5):1957-1966, 2012
65. Bellardita L, Donegani S, Spatuzzi AL, **Valdagni R**. Multidisciplinary Versus One-on-One Setting: A Qualitative Study of Clinicians' Perceptions of Their Relationship With Patients With Prostate Cancer. *J Oncol Pract* 7(1):e1-5 2011
66. **Valdagni R**, Albers P, Bangma C, Drudge-Coates L, Magnani T, Moynihan C, Parker C, Redmond K, Sternberg CN, Denis L, Costa A. The requirements of a specialist Prostate Cancer Unit: a discussion paper from the European School of Oncology. *Eur J Cancer* 47:1, 1-7, 2011
67. Procopio G, Guadalupi V, Giganti MO, Mariani L, Salvioni R, Nicolai N, Capone F, **Valdagni R**, Bajetta E. Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration. *BJU Int* 108 (2):223-7, 2011
68. Folini M, Gandellini P, Longoni N, Profumo V, Callari M, Pennati M, Colecchia M, Supino R, Veneroni S, Salvioni R, **Valdagni R**, Daidone MG, Zaffaroni N. miR-21: an oncomir on strike in prostate cancer. *Mol Cancer* 21:9-12, 2010
69. Van den Bergh RC, Vasarainen H, van der Poel HG, Vis-Maters JJ, Rietbergen JB, Pickles T, Cornel EB, **Valdagni R**, Jaspars JJ, van der Hoeven J, Staerman F, Oomens EH, Rannikko A, Roemeling S, Steyerberg EW, Roobol MJ, Schröder FH, Bangma CH. Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study. *BJU Int* 105: 956-962, 2010
70. Fellin G, Fiorino C, Rancati T, Vavassori V, Baccolini M, Bianchi C, Cagna E, Gabriele P, Mauro F, Menegotti L, Monti A, Stasi M, **Valdagni R**. Clinical and dosimetric predictors of late rectal toxicity after conformal radiation for localized prostate cancer: results of a large multi-center observational study. *Radiother Oncol* 93:197-202, 2009
71. Fiorino C, **Valdagni R**, Rancati T, Sanguineti G. Dose-volume effects for normal tissues in external radiotherapy: pelvis. *Radiother Oncol* 93:153-167, 2009
72. Pilla L, Rivoltini L, Patuzzo R, Marrari A, **Valdagni R**, Parmiani G. Multipptide vaccination in cancer patients. *Expert Opin Biol Ther* 9:1043-1055, 2009
73. Fiorino C, Rancati T, **Valdagni R**. Predictive models of toxicity in external radiotherapy: dosimetric issues. *Cancer* 115:3135-3140, 2009

74. **Valdagni R**, Rancati T, Fiorino C. Predictive models of toxicity with external radiotherapy for prostate cancer: Clinical issues. *Cancer* 115:3141-3149, 2009
75. **Valdagni R**, Scardino PT, Denis L. The 2008 European School of Oncology Inside Track Conference "Predictive modeling in prostate cancer". *Cancer* 115:3035-3038, 2009
76. Iero M, Filipazzi P, Castelli C, Belli F, **Valdagni R**, Parmiani G, Patuzzo R, Santinami M, Rivoltini L. Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumor immunity? *Cancer Immunol Immunother* 58:1159-1167, 2009
77. **Valdagni R**, Rancati T, Ghilotti M, Cozzarini C, Vavassori V, Fellin G, Fiorino C, Girelli G, Barra S, Zaffaroni N, Pierotti MA, Gariboldi M. To bleed or not to bleed. A prediction based on individual gene profiling combined with dose-volume histogram shapes in prostate cancer patients undergoing three-dimensional conformal radiation therapy. *Int J Radiat Oncol Biol Phys* 74:1431-1440, 2009
78. Di Muzio N, Fiorino C, Cozzarini C, Alongi F, Broggi S, Mangili P, Guazzoni G, **Valdagni R**, Calandrino R, Fazio F. Phase I-II study of hypofractionated simultaneous integrated boosts with tomotherapy for prostate cancer. *Int J Radiat Oncol Biol Phys* 74:392-398, 2009
79. Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, Salvioni R, Supino R, Moretti R, Limonta P, **Valdagni R**, Daidone MG, Zaffaroni N. MiR-205 exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase cepsilon. *Cancer Res* 69:2287-2295, 2009
80. Begnozzi L, Benassi M, Bertanelli M, Bonini A, Cionini L, Conte L, Fiorino C, Gabriele P, Gardani G, Giani A, Magri S, Morelli M, Morrica B, Olmi P, Orecchia R, Penduzzo G, Raffaele L, Rosi A, Tabocchini MA, **Valdagni R**, Viti V. Quality assurance of 3D-CRT: indications and difficulties in their applications. *Crit Rev Oncol Hematol* 70:24-38, 2009
81. Gatta G, Zigon G, Buemi A, Coebergh W, Colonna M, Contiero P, Denis L, Grosclaude P, Guizard AV, Sanchez-Perez MJ, Plesko I, Ondrusova M, Rachtan J, **Valdagni R**, Velten M, Vercelli M, Berrino F. Prostate cancer treatment in Europe at the end of the 1990s. *Acta Oncol* 48:867-873, 2009
82. **Valdagni R**, Scardino PT, Denis L, Kattan MW. Predictive Modeling in Prostate Cancer: A Conference Summary. *Eur Urol* 55: 300-302, 2009
83. Fiorino C, Alongi F, Broggi S, Cattaneo MG, Cozzarini C, Di Muzio N, Maggiulli E, Mangili P, Perna L, **Valdagni R**, Fazio F, Calandrino R. Physics aspects of prostate tomotherapy: Planning optimization and image-guidance issues. *Acta Oncol* 5: 1309-1316, 2008
84. Aristei C, Amichetti M, Ciocca M, Nardone L, Bertoni F, Vidali C, Italian Society of Radiation Oncology (**Valdagni R**). Radiotherapy in Italy after conservative treatment of early breast cancer. A survey by the Italian Society of Radiation Oncology (AIRO). *Tumori* 94: 333-341, 2008
85. Cozzarini C, Fiorino C, Di Muzio N, **Valdagni R**, Salonia A, Alongi F, Broggi S, Guazzoni G, Montorsi F, Rigatti P, Calandrino R, Fazio F. Hypofractionated adjuvant radiotherapy with helical Tomotherapy after radical prostatectomy: Planning data and toxicity results of a Phase I-II study. *Radiother Oncol* 88: 26-33, 2008
86. Fiorino C, Di Muzio N, Broggi S, Cozzarini C, Maggiulli E, Alongi F, **Valdagni R**, Fazio F, Calandrino R. Evidence of limited motion of the prostate by carefully emptying the rectum as assessed by daily MVCT image guidance with helical tomotherapy. *Int J Radiat Oncol Biol Phys* 71:611-617, 2008
87. **Valdagni R**, Rancati T, Fiorino C, Fellin G, Magli A, Baccolini M, Bianchi C, Cagna E, Greco C, Mauro FA, Monti AF, Munoz F, Stasi M, Franzone P, Vavassori V. Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D-CRT. *Int J Radiat Oncol Biol Phys* 71: 1065-1073, 2008
88. Fiorino C, Fellin G, Rancati T, Vavassori V, Bianchi C, Borca C V, Girelli G, Mapelli M, Menegotti L, Nava S, **Valdagni R**. Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: preliminary results of a multicenter prospective study. *Int J Radiat Oncol Biol Phys* 70(4):1130-1137, 2008
89. Inghelmann R, Grande E, Francisci S, Verdecchia A, Micheli A, Baili P, Gatta G, Capocaccia R, **Valdagni R**, De Angelis R. Regional estimates of prostate cancer burden in Italy. *Tumori* 93:380-386, 2007
90. Cionini L, Gardani G, Gabriele P, Magri S, Morosini PL, Rosi A, Viti V, Italian Working Group General Indicators (**Valdagni R**). Quality Indicators in Radiotherapy. *Radiother Oncol* 82:191-200, 2007
91. Vavassori V, Fiorino C, Rancati T, Magli A, Fellin G, Baccolini M, Bianchi C, Cagna E, Mauro FA, Monti A, Munoz F, Stasi M, Franzone P, **Valdagni R**. Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: Results of a prospective multicenter study. *Int J Radiat Oncol Biol Phys* 67:1401-1410, 2007
92. Marrari A, Iero M, Pilla L, Villa S, Salvioni R, **Valdagni R**, Parmiani G, Rivoltini L. Vaccination therapy in prostate cancer. *Cancer Immunol Immunother* 56:429-445, 2007
93. Stasi M, Munoz F, Fiorino C, Pasquino M, Baiotto B, Marini P, Malinverni G, **Valdagni R**, Gabriele P. Emptying the rectum before treatment delivery limits the variations of rectal dose - volume parameters during 3DCRT of prostate cancer. *Radiother Oncol* 80:363-370, 2006
94. Bracarda S, De Cobelli O, Greco C, Prayer-Galetti T, **Valdagni R**, Gatta G, de Braud F, Bartsch G. Cancer of the prostate. *Crit Rev Oncol Hematol* 56: 379-396, 2005
95. **Valdagni R**, Salvioni R, Nicolai N, Villa S, Bedini N, Bajetta E, Procopio G, Donegani S, Bosisio M. In reference to Kagan AR: "The multidisciplinary clinic". *Int J Radiat Oncol Biol Phys* 63: 309-310, 2005

96. Malinverni G, Greco C, Bianchi P, Busutti L, Cagna E, Cozzarini C, Del Duca M, Frezza G, Gabriele P, Genovesi D, Girelli GF, Italia C, Mandoliti G, Mauro F, Nava S, Pratisoli S, Saracino MB, Squillace L, Signor M, Tagliagambe A, Vavassori V, Villa S, Zini G, **Valdagni R**. Italian survey in postoperative radiation therapy for prostate carcinoma by the AIRO national working group on prostate radiotherapy: definitive results. *Tumori* 91: 156-162, 2005
97. **Valdagni R**, Italia C, Montanaro P, Lanceni A, Lattuada P, Magnani T, Fiorino C, Nahum A. Is the alpha-beta ratio of prostate cancer really low? A prospective, non randomized trial comparing standard and hyperfractionated conformal radiation therapy. *Radiother Oncol* 75: 74-82, 2005
98. Fiorino C, Sanguineti G, **Valdagni R**. Fractionation and late rectal toxicity: No reliable estimates of  $\alpha/\beta$  value for rectum can be derived from studies where different volumes of rectum are irradiated at different dose levels: In regard to Brenner. *Int J Radiat Oncol Biol Phys* 62: 289-291, 2005
99. Rancati T, Fiorino C, Gagliardi G, Cattaneo GM, Sanguineti G, Casanova Borca V, Cozzarini C, Fellin G, Foppiano F, Girelli G, Menegotti L, Piazzolla A, Vavassori V, **Valdagni R**. Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101). *Radiother Oncol* 73: 21-32, 2004
100. Bauman G, Rodrigues G, Fiorino C, Sanguineti G, **Valdagni R**. In regard to Fiorino et al.: Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. *Int J Radiat Oncol Biol Phys* 59: 914-915, 2004
101. Fiorino C, Sanguineti G, Cozzarini C, Fellin G, Foppiano F, Menegotti L, Piazzolla A, Vavassori V, **Valdagni R**. Rectal Dose-Volume Constraints in High-Dose Radiotherapy of Localized Prostate Cancer. *Int J Radiat Oncol Biol Phys* 57/4: 953-962, 2003
102. de Braud F, Khayat D, Kroon BBR, **Valdagni R**, Bruzzi P, Cascinelli N. Malignant Melanoma. *Crit Rev Oncol Hematol* 47: 35-63, 2003
103. Foppiano F, Fiorino C, Frezza G, Greco C, **Valdagni R**, AIRO National Working Group on Prostate Radiotherapy. The Impact of Contouring Uncertainty on Rectal 3D Dose-Volume Data: Results of a Dummy Run in a Multi-centric Trial (AIROPROS01-02). *Int J Radiat Oncol Biol Phys* 57/2: 573-589, 2003
104. Amichetti M, Zurlo A, Cristoforetti L, **Valdagni R**. Prognostic Significance of Cervical Lymph Nodes Density Evaluated by Contrast Computer Tomography in Head and Neck Squamous Cell Carcinoma Treated with Hyperthermia and Radiotherapy. *Int J Hyperthermia* 16, 6: 539-547, 2000
105. Amichetti M, Romano M, Cristoforetti L, **Valdagni R**. Hyperthermia and Radiotherapy for Inoperable Squamous Cell Carcinoma Metastatic to Cervical Lymph Nodes from an Unknown Primary Site. *Int J Hyperthermia* 16, 1: 85-93, 2000
106. **Valdagni R**, Amichetti M, Ciocca M. Patterns of radiotherapy for early breast cancer in Northern Italy compared with European and national standards. *Radiother Oncol* 51: 79-85, 1999
107. Amichetti M, Caffo O, Richetti A, Zini G, Rigon A, Antonello M, Roncadin M, Coghetto F, **Valdagni R**, Fasan S, Maluta S, Di Marco A, Neri S, Vidali C, Panizzoni G, Aristei C. Subclinical Ductal Carcinoma in Situ of the Breast: Treatment with Conservative Surgery and Radiotherapy. *Tumori* 85: 488-493, 1999
108. **Valdagni R**, Bertoni F, Bossi A, Caraffini B, Corbella F, Italia C, Kalli M, Leoni M, Nava S, Sarti E, Vavassori V, Villa S. Minimal Requirements in Prostate Cancer Irradiation: a Consensus Document by the AIRO Lombardia Cooperative Group. *Tumori* 85: 143-148, 1999
109. Italia C, Fiorino C, Ciocca M, Cattaneo GM, Montanaro P, Bolognesi A, Lanceni A, Reni M, Bovini A, Modugno A, Calandrino R, **Valdagni R**. Quality control by portal film analysis in radiotherapy for prostate cancer: a comparison between two different institutions and treatment techniques. *Tumori* 84:640-648, 1998
110. deCataldo F, Baudo F, Ottonelli C, Italia C, **Valdagni R**. Complete Regression of a Suprasellar Secondary Mass in a Patient with Low-Grade Non-Hodgkin's Lymphoma (NHL) Treated with 2-Chlorodeoxyadenosine (CDA). *Am J Hematol* 57: 258-259, 1998
111. **Valdagni R**. Altered Fractionation in Radiotherapy. *Tumori* 84: 155-159, 1998
112. Amichetti M, Romano M, Busana L, Bolner A, Fellin G, Pani G, Tomio L, **Valdagni R**. Hyperfractionated Radiation in Combination with Local Hyperthermia in the Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck: a Phase I-II Study. *Radiother Oncol* 45: 155-159, 1997
113. Amichetti M, Caffo O, Richetti A, Zini G, Rigon A, Antonello M, Arcicasa M, Coghetto F, **Valdagni R**, Maluta S, Di Marco A. Ten-Year Results of Treatment of Ductal Carcinoma in Situ (DCIS) of the Breast with Conservative Surgery and Radiotherapy. *Eur J Cancer* 3: 1559-1565, 1997
114. Amichetti M, Caffo O, Richetti A, Zini G, Rigon A, Lora O, Antonello M, Arcicasa M, Roncadin M, Coghetto F, Zorat P, **Valdagni R**, Balli M, Panizzoni G, Maluta S, Di Marco A, Favretto S, Teodorani N, Neri S, Fasan S. Treatment of Intraductal Carcinoma of the Breast with Conservative Surgery and Radiotherapy: an Italian Multicentre Retrospective Study. *Radiother Oncol* 31: 109-111, 1997
115. **Valdagni R**, Italia C, Montanaro P, Ciocca M, Morandi G, Salvadori B. Clinical Target Localization using Conventional Methods (anatomy and palpation) and Ultrasonography in Early Breast Cancer Post-operative External Irradiation. *Radiother Oncol* 42: 231-237, 1997
116. Amichetti M, Graiff C, Romano M, Bolner A, Busana L, Fellin G, Pani G, **Valdagni R**. Ipertermia e Radioterapia Palliative dei Sarcomi. *Radiol Med* 91: 796-798, 1996

117. **Valdagni R**, Ciocca M, Italia C, Montanaro P, Lanceni A, Modugno A. Aspetti Clinico-metodologici di Assicurazione della Qualità nella Radioterapia Esterna: Ottimizzazione del Trattamento Radiante nel Cancro Precoce della Mammella. *Radiol Med* 92: 462-469, 1996
118. **Valdagni R**, Arcangeli G. Past and Present of Radiation Oncology in Italy. *Int J Radiat Oncol Biol Phys* 35, 3: 609-614, 1996
119. Bolner A, Valentini A, Amichetti M, Busana L, Fellin G, Menegotti L, Nassivera E, Pani G, Romano M, **Valdagni R**. La Radioterapia nelle Neoplasie T1N0 della Glottide. *Radiol Med* 90: 804-807, 1995
120. Gabriele P, Amichetti M, Orecchia R, **Valdagni R**. Hyperthermia and Radiation Therapy for Inoperable or Recurrent Parotid Carcinoma: A Phase I-II Study. *Cancer* 75: 908-913, 1995
121. Palazzi M, **Valdagni R**, Poli M, Buffoli A, Leone M, Vavassori V, Di Lorenzo I, Corbella F, Nava S, Cazzaniga LF, d'Affronto C, Di Muzio N, Borsa G. The Role of Radiotherapy in the Treatment of Stage III Non-Small Cell Lung Cancer: a Survey of Clinical Practices in Lombardy, Italy, by the AIRO-Lombardia Cooperative Group. *Tumori* 80: 286-289, 1994
122. **Valdagni R**, Amichetti M. Report of Long-term Follow Up in a Randomized Trial Comparing Radiation Therapy and Radiation Therapy plus Hyperthermia to Metastatic Lymphnodes in Stage IV Head and Neck Patients. *Int J Radiat Oncol Biol Phys* 28: 163-169, 1994
123. Amichetti M, Graiff C, Fellin G, Pani G, Bolner A, Maluta S, **Valdagni R**. Cisplatin, Hyperthermia and Radiation (Trimodal Therapy) in Patients with Locally Advanced Head and Neck Tumors: A Phase I-II Study. *Int J Radiat Oncol Biol Phys* 26:801-807, 1993
124. Scielzo G, Ciocca M, Zonca G, Maggi S, Ascione B, Grillo Ruggieri F, **Valdagni R**, Sverzellati PE, Spiga G, Miolo L, Brunelli B. Confronto tra i Test di Accettazione di Cinque Acceleratori Lineari di Elettroni per Radioterapia. *Radiol Med* 83: 804-809, 1992
125. **Valdagni R**, Ciocca M, Busana L, Modugno A, Italia C. Beam Modifying Devices in the Treatment of Early Breast Cancer: 3-D Stepped Compensating Technique. *Radiother Oncol* 23: 192-195, 1992
126. Bagshaw MA, Kaplan ID, **Valdagni R**, Cox RS. Radiation treatment of prostate bone metastases and the biological considerations. *Adv Exp Med Biol* 324: 255-268, 1992
127. **Valdagni R**, Italia C. Early Breast Cancer after Conservative Surgery: Quality Control by Portal Localization Films. *Radiother Oncol* 22: 311-313, 1991
128. Ciocca M, Landoni L, Italia C, Montanaro P, Canesi P, **Valdagni R**. Quality Control in the Conservative Treatment of Breast Cancer: Patient Dosimetry Using Silicon Detectors. *Radiother Oncol* 22: 304-307, 1991
129. **Valdagni R**. The International Consensus Meeting on Hyperthermia. *Am J Clin Oncol* 14, 3: 267-269, 1991
130. Amichetti M, **Valdagni R**, Graiff C, Valentini A. Local-Regional Recurrences of Breast Cancer: Treatment with Radiation Therapy and Local Microwave Hyperthermia. *Am J Clin Oncol* 14, 1: 60-65, 1991
131. **Valdagni R**. Response to Parsons. *Int J Radiat Oncol Biol Phys* 20: 1379-1382, 1991
132. **Valdagni R**, Ciocca M, Italia C, Fantin PL, Landoni L, Canesi P. Schermature Personalizzate in Lega Bassofondente per Elettroni di Alta Energia nel Trattamento di Neoplasie Superficiali situate in Regioni Estetiche o Critiche. *Radiol Med, Suppl.* 1 al N. 4: 46-51, 1990
133. Pontalti R, Cristoforetti L, **Valdagni R**, Antolini R. Absorption Rate Density (ARD) Computation in Microwave Hyperthermia by the Finite-Difference Time-Domain Method. *Phys Med Biol* 35: 891-904, 1990
134. Kaplan ID, **Valdagni R**, Cox RS, Bagshaw MA. Reduction of Spinal Metastases after Preemptive Irradiation in Prostatic Cancer. *Int J Radiat Oncol Biol Phys* 18: 1019-1025, 1990
135. **Valdagni R**, Liu FF. Evaluating Radiation in Combination with Hyperthermia Trials: the Importance of Clinical and Technical Parameters. *Tumori* 76: 205-211, 1990
136. **Valdagni R**, Amichetti M. Radiation Therapy of Carotid Body Tumors. *Am J Clin Oncol* 13:45-48, 1990
137. **Valdagni R**, International Consensus Meeting on Hyperthermia. Final Report. *Int J Hyperthermia* 6: 837-877, 1990
138. **Valdagni R**, Liu FF, Kapp DS. Important Prognostic Factors Influencing Outcome of Combined Radiation and Hyperthermia. *Int. J Radiat Oncol Biol Phys* 15: 959-972, 1988
139. **Valdagni R**, Amichetti M, Pani G. Radical Radiation alone versus Radical Radiation plus Microwave Hyperthermia for N3 (TNM-UICC) Neck Nodes: a Prospective Randomized Clinical Trial. *Int J Radiat Oncol Biol Phys* 15:13-24, 1988
140. **Valdagni R**, Amichetti M, Cristoforetti L. Intracavitary Hyperthermia: Construction and Heat Patterns of Individualized Vaginal Prototype Applicators. *Int J Hyperthermia* 4: 457-466, 1988
141. Amichetti M, Piffer S, **Valdagni R**, Ambrosini G, Piazza M. Peripheral DTIC Neurotoxicity: a case report. *Cancer Chemoter Pharmacol* 19: 87-88, 1987
142. **Valdagni R**. Current Status of Clinical Hyperthermia. *Int J Hyperthermia*, 3: 594-595, 1987
143. **Valdagni R**, Amichetti M. Clinical Hyperthermia: Five Year's Experience. *Strahlenther Onkol* 163, 7: 443-445, 1987

144. Samulski TV, Fessenden P, **Valdagni R**, Kapp DS. Correlations of Thermal Washout Rate, Steady State Temperatures and Tissue Type in Deep Seated Recurrent or Metastatic Tumors. *Int J Radiat Oncol Biol Phys* 13: 907-916, 1987
145. Amichetti M, Bolner A, Busana L, Fellin G, Pani G, Piffer S, **Valdagni R**, Ambrosini G. Neoadjuvant Chemotherapy with Vincristine, Bleomycin and Methotrexate combined with Radiotherapy in Advanced Head and Neck Squamous Cell Carcinoma. *Tumori* 72: 301-306, 1986
146. **Valdagni R**, Kapp DS, Valdagni C. N3 (TNM-UICC) Metastatic Neck Nodes Managed by Combined Radiation Therapy and Hyperthermia: Clinical Results and Analysis of Treatment Parameters. *Int J Hyperthermia* 2: 189-200, 1986
147. **Valdagni R**. L'ipertermia nella Cura dei Tumori Maligni. *Radiol Med*, 68: 527-528, 1982
148. **Valdagni R**, Amichetti M, Dell'Orsola G. Local Microwave Hyperthermia in Cancer Therapy. Preliminary Report. *Tumori*, 68: 247-251, 1982